Literature DB >> 11119894

Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients.

R H Hu1, P H Lee, M K Tsai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11119894     DOI： 10.1016/s0041-1345(00)01413-5

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  9 in total

Review 1.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Authors:  Alex Ganetsky; Todd A Miano; Mitchell E Hughes; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  J Antimicrob Chemother       Date:  2015-04-16       Impact factor: 5.790

3.  Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.

Authors:  Marie Antignac; Jean Sebastien Hulot; Emmanuel Boleslawski; Laurent Hannoun; Yvan Touitou; Robert Farinotti; Philippe Lechat; Saïk Urien
Journal:  Eur J Clin Pharmacol       Date:  2005-07-01       Impact factor: 2.953

4.  Effect of CYP3A5 genotype on hospitalization cost for kidney transplantation.

Authors:  Suda Vannaprasaht; Chulaporn Limwattananon; Sirirat Anutrakulchai; Chitranon Chan-On
Journal:  Int J Clin Pharm       Date:  2018-11-16

5.  Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real-world data and simulated data.

Authors:  Michael L Williams; Hannah L Weeks; Cole Beck; Kelly A Birdwell; Sara L Van Driest; Leena Choi
Journal:  Br J Clin Pharmacol       Date:  2022-01-27       Impact factor: 3.716

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.

Authors:  Xiang-guang Meng; Cheng-xian Guo; Guo-qing Feng; Ying-chun Zhao; Bo-Ting Zhou; Jian-le Han; Xin Chen; Yong Shi; Hong-yao Shi; Ji-ye Yin; Xiang-dong Peng; Qi Pei; Wei Zhang; Guo Wang; Meng He; Min Liu; Jing-ke Yang; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150

9.  Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.

Authors:  P Dalal; G Shah; D Chhabra; Lorenzo Gallon
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-08-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.